Cangene Receives Approval for WinRho
Complete the form below to unlock access to ALL audio articles.
Cangene Corporation has announced that the company's wholly owned subsidiary, Cangene Europe Limited, has received marketing authorization approval for WinRho® 1500 LQ in Portugal from the National Authority of Medicines and Health Products, IP (INFARMED).
The Company has received a national license to market the product in Portugal for two indications: to prevent Rho(D) immunization women that are in Rho(D) negative, and to treat Rho(D) negative patients after incompatible Rho(D) positive blood transfusions or other products containing erythrocytes antigens.
John A. Sedor, President and CEO of Cangene, said: "Today's approval is a milestone for Cangene and significant news for expectant mothers and other Rh-negative patients in Portugal. By bringing WinRho to Portugal, we have reestablished a foothold in Europe as we drive the growth of Cangene's flagship product in markets outside of North America."
The product will be distributed nationally in Portugal by a third party distributor on behalf of Cangene.
